
Sight Sciences Inc
Prices are adjusted according to historical splits.

Vitals
- Today's Low:
- $3.06
- Today's High:
- $4.04
- Open Price:
- $3.81
- 52W Low:
- $3.06
- 52W High:
- $15.295
- Prev. Close:
- $6.51
- Volume:
- 2872462
Company Statistics
- Market Cap.:
- $318.18 million
- Book Value:
- 2.798
- Revenue TTM:
- $81.52 million
- Operating Margin TTM:
- -87.9%
- Gross Profit TTM:
- $58.97 million
- Profit Margin:
- -87.05%
- Return on Assets TTM:
- -21.02%
- Return on Equity TTM:
- -43.28%
Company Profile
Sight Sciences Inc had its IPO on 2021-07-15 under the ticker symbol SGHT.
The company operates in the Healthcare sector and Medical Devices industry. Sight Sciences Inc has a staff strength of 250 employees.
Stock update
Shares of Sight Sciences Inc opened at $3.81 at the start of the last trading session i.e. 2023-09-12.
The stocks traded within a range of $3.06 - $4.04, and closed at $3.28.
This is a -49.62% slip from the previous day's closing price.
A total volume of 2,872,462 shares were traded at the close of the day’s session.
In the last one week, shares of Sight Sciences Inc have slipped by -49.85%.
Sight Sciences Inc's Key Ratios
Sight Sciences Inc has a market cap of $318.18 million, indicating a price to book ratio of 3.3746 and a price to sales ratio of 9.8107.
In the last 12-months Sight Sciences Inc’s revenue was $81.52 million with a gross profit of $58.97 million and an EBITDA of $-71022000. The EBITDA ratio measures Sight Sciences Inc's overall financial performance and is widely used to measure its profitability.
In the trailing 12-month period, Sight Sciences Inc’s operating margin was -87.9% while its return on assets stood at -21.02% with a return of equity of -43.28%.
In Q2, Sight Sciences Inc’s quarterly earnings growth was a positive 0% while revenue growth was a positive 36.2%.
Sight Sciences Inc’s PE and PEG Ratio
- Forward PE
- 0
- Trailing PE
- 0
- PEG
Its diluted EPS in the last 12-months stands at $-1.47 per share while it has a forward price to earnings multiple of 0 and a PEG multiple of . A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.
The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into Sight Sciences Inc’s profitability.
Sight Sciences Inc stock is trading at a EV to sales ratio of 6.386 and a EV to EBITDA ratio of -5.221. Its price to sales ratio in the trailing 12-months stood at 9.8107.
Sight Sciences Inc stock pays annual dividends of $0 per share, indicating a yield of 0% and a payout ratio of 0%.
Balance sheet and cash flow metrics
- Total Assets
- $185.29 million
- Total Liabilities
- $14.05 million
- Operating Cash Flow
- $0
- Capital Expenditure
- $97000
- Dividend Payout Ratio
- 0%
Sight Sciences Inc ended 2025 with $185.29 million in total assets and $0 in total liabilities. Its intangible assets were valued at $185.29 million while shareholder equity stood at $136.13 million.
Sight Sciences Inc ended 2025 with $0 in deferred long-term liabilities, $14.05 million in other current liabilities, 49000.00 in common stock, $-271064000.00 in retained earnings and $0 in goodwill. Its cash balance stood at $154.52 million and cash and short-term investments were $154.52 million. The company’s total short-term debt was $1,064,000 while long-term debt stood at $33.61 million.
Sight Sciences Inc’s total current assets stands at $182.32 million while long-term investments were $0 and short-term investments were $0. Its net receivables were $18.10 million compared to accounts payable of $2.95 million and inventory worth $7.91 million.
In 2025, Sight Sciences Inc's operating cash flow was $0 while its capital expenditure stood at $97000.
Comparatively, Sight Sciences Inc paid $0 in dividends in 2025.
Other key metrics
- Current Trading Price
- $3.28
- 52-Week High
- $15.295
- 52-Week Low
- $3.06
- Analyst Target Price
- $10.48
Sight Sciences Inc stock is currently trading at $3.28 per share. It touched a 52-week high of $15.295 and a 52-week low of $15.295. Analysts tracking the stock have a 12-month average target price of $10.48.
Its 50-day moving average was $7.45 and 200-day moving average was $9.65 The short ratio stood at 4.34 indicating a short percent outstanding of 0%.
Around 2155.7% of the company’s stock are held by insiders while 5964.2% are held by institutions.
Frequently Asked Questions About Sight Sciences Inc
Similar Industry Stocks (Medical Devices)
Most Active
Top Gainers
Top Losers
About
Sight Sciences, Inc., an ophthalmic medical device company, engages in the development and commercialization of surgical and nonsurgical technologies for the treatment of eye diseases. The company’s products include OMNI Surgical System, a therapeutic device used by ophthalmic surgeons to reduce intraocular pressure in adult glaucoma patients; and TearCare System, a wearable eyelid technology for the treatment of dry eye disease (DED) for ophthalmologists and optometrists. It offers its products through sales representatives and distributors to hospitals, medical centers, and eyecare professionals in the United States. Sight Sciences, Inc. was incorporated in 2010 and is headquartered in Menlo Park, California.